arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Programme

Thursday 10 Nov

08:30

Registration

09:00

Opening/Welcome

René Leemans/Andreas Dietz/Wojciech Golusinski

Epidemiology and carcinogenesis

Chairs: Andreas Dietz/Wojciech Golusinski

09:20

Epidemiology of oral/oropharyngeal HPV infection

Maura Gillison

09:40

HPV-mediated carcinogenesis

Ruud Brakenhoff

10:00

Worldwide incidence of HPV in OPSCC

Pawel Golusinski

10:20

Coffee

10:50

Mucosal stem cells and HPV infection

Jochen Hess

11:10

Free papers 4x

Prognosis and serology HPV in OPSCC

Chairs: Ruud Brakenhoff/ Maura Gillison

11:50

Validation of statistical models for OPSCC

Robert Baatenburg de Jong

12:10

Subclassification of HPV-OPSCC by gene expression

Lisa Licitra

12:30

HPV early antigen serology and OPC screening

Tim Waterboer

12:45

Antibody producing B-cells in HPV+ve OPSCC: an overview

Rieneke van de Ven

13:00

Lunch

13:30

Satellite symposium

Treatment of HPV+ve OPSCC

Chairs: René Leemans/Hans Langendijk

14:30

Treatment of HPV disease by transoral robotic surgery

Christian Simon

14:50

Treatment of HPV disease by laser surgery

Terry Jones

15:10

Treatment of HPV disease with (chemo)radiotherapy

Vincent Gregoire

15:30

Free papers 3x

16:00

Coffee

Chairs: Christian Simon/Stephan Lang

16:30

Are there alternatives for 3 weekly cisplatin in HPV disease?

Jan Vermorken

16:50

Salvage surgery for HPV disease

Carole Fakhry

Debate

17:10

Debate: This house believes that TNM8 was implemented too early for HPV+ve OPSCC

For: Hisham Mehanna / Against: Brian O’Sullivan

17:00

Posters and Drinks

19:00

Social evening (dinner)

Friday 11 Nov

Future perspectives in HPV research

Chairs: Rieneke van de Ven/Ingeborg Tinhofer-Keilholz

09:00

Free papers 3x

09:30

HPV in non-oropharygeal HNSCC: does it play a role?

Gunnar Wichmann

09:50

Therapeutic HPV vaccination

Sjoerd van der Burg

HPV16+ OPSCC patients display an overall longer survival and a lower recurrence rate after standard of care treatment than HPV- patients.  Because the composition of the tumor immune microenvironment (TIME) associated with good prognosis generally also predicts the success of immunotherapy, we started  to analyze an unique prospective cohort of HPV- and HPV+  OPSCC patients. We found that clinical outcome is strongly linked to the presence of HPV-specific CD4+ and CD8+ tumor infiltrating lymphocytes (TIL) during >10 years follow-up. New evidence, suggests that immunity is not only targeted at the E6 and E oncoproteins but may also involve the E2 protein. Subsequently, we performed a comprehensive multimodal, high-dimensional strategy to dissect the TIME of treatment-naïve IR+ and IR− OPSCC tissue, including bulk RNA sequencing, imaging mass cytometry and combined single-cell gene expression profiling and T-cell receptor of TIL. This revealed that IR+ tumors expressed higher levels of genes strongly related to interferon gamma signaling, T-cell activation, TCR-signaling, and mononuclear cell differentiation, as well as several immune signaling pathways, than IR− patients, specifically related to ectopic lymphoid structure development. Moreover, scRNAseq identified a subset of clonally expanded CD8+ T cells, dominantly present in IR+ tumors, which secreted T-cell and DC-attracting chemokines. Immune cell infiltration in IR+ tumors is stronger, highly coordinated, and has a distinct spatial phenotypical signature characterized by intra-tumoral microaggregates of CD8+CD103+ and CD4+ T-cells with DCs. In contrast, the IR− TIME comprised spatial interactions between lymphocytes and various immunosuppressive myeloid cell populations, which differed per patient. The impact of these results are discussed in view of our previous and current trials with (combinations of) therapeutic vaccination and checkpoint strategies.

Sjoerd van der Burg

Sjoerd van der Burg

Head Of Research Laboratories, Senior Investigator Oncode Institute

Therapy developments in HPV+ve OPSCC

Chairs: Jan Vermorken/Vincent Gregoire

10:10

De-escalation of non-surgical therapy

Hisham Mehanna

10:30

Coffee

11:00

Free papers 2x

11:20

Immunotherapy for HPV driven disease

Maura Gillison

11:40

Is proton therapy preferable for HPV+ve OPSCC?

Hans Langendijk

12:00

Tumor board (moderator: Terry Jones)

Wojciech Golusinski, Stephan Lang, Hans Langendijk, Lisa Licitra, Bob Ferris

13:00

Lunch

Therapy developments in HPV+ve OPSCC

Chairs: Lisa Licitra/Hans Langendijk

14:00

Cell therapy for HPV-driven disease

Christian Hinrichs

14:20

De-escalation using surgery

Bob Ferris

14:40

Free papers 3x

Screening and Prevention

Chair: Andreas Dietz

15:10

Round table screening and prevention

Discussion leader: Andreas Dietz

5-slide Pitch Hans Berkhof: Preventive vaccination, also in treated OPSCC patients?
5-slide Pitch Tim Waterboer: HPV serology for screening
5-slide Pitch Ingeborg Tinhofer-Keilholz: HPV DNA assays for screening
5-slide Pitch Carole Fakhry: Positively screened for HPV: which intervention?

16:00

Round table discussion: screening and prevention

16:30

Summary

Wojciech Golusinski

16:40

Free paper/Poster awards and closing remarks

René Leemans

16:50

Adjourn